Related Experiment Video
Updated: Aug 16, 2026
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
An Adaptable Nanoprobe Integrated with Quantitative T1 -Mapping MRI for Accurate Differential Diagnosis of
Aijun Shen1, Yanhong Sun2,3, Gangmin Wang4
1Department of Medical Imaging, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Abstract:
Multidrug resistance (MDR) is one of the major factors causing failure of non-small-cell lung cancer (NSCLC) chemotherapy. Real-time and accurate differentiation between drug-resistant and sensitive NSCLC is of primary importance for guiding the subsequent treatments and improving the therapeutic outcome. However, there is no effective method to provide such an accurate differentiation. This study creates an innovative strategy of integrating H2 O2 -responsive nanoprobes with the quantitative T1 -mapping magnetic resonance imaging (MRI) technique to achieve an accurate differential diagnosis between drug-resistant and sensitive NSCLC in light of differences in H2 O2 content in the tumor microenvironment (TME). The result demonstrates that the synthesized MIL-53(Fe)@MnO2 nanocomposites possess an excellent capability of shortening the cancer longitudinal relaxation time (T1 ) when meeting H2 O2 in TME. T1 -mapping MRI could sensitively detect this T1 variation (about 2.6-fold that of T1-weighted imaging (T1 WI)) to accurately differentiate the H2 O2 content between drug-resistant and sensitive NSCLC. In addition, the quantitative data provided by the T1 -mapping MRI dedicates correct comparison across imaging tests and is more reliable than T1 WI, thus giving it a chance for precise assessment of the anti-cancer effect. This innovative strategy of merging TME adaptable nanoprobes with the quantitative MRI technique provides a new approach for the precise diagnosis of multidrug-resistant NSCLC.
Insights
This study developed a new method using H2O2-responsive nanoprobes and T1-mapping MRI to distinguish drug-resistant from sensitive non-small cell lung cancer (NSCLC). This approach accurately differentiates NSCLC based on tumor microenvironment hydrogen peroxide levels.
Area of Science:
- Biomedical Imaging
- Nanotechnology
- Oncology
Background:
- Multidrug resistance (MDR) significantly hinders non-small cell lung cancer (NSCLC) chemotherapy efficacy.
- Accurate real-time differentiation between drug-resistant and sensitive NSCLC is crucial for treatment guidance and improved outcomes.
- Current methods lack the precision for effective differential diagnosis of NSCLC drug resistance.
Purpose of the Study:
- To develop an innovative strategy for accurate differential diagnosis of drug-resistant and sensitive NSCLC.
- To leverage differences in hydrogen peroxide (H2O2) content within the tumor microenvironment (TME) for diagnosis.
- To integrate H2O2-responsive nanoprobes with quantitative T1-mapping magnetic resonance imaging (MRI).
Main Methods:
- Synthesis of MIL-53(Fe)@MnO2 nanocomposites as H2O2-responsive nanoprobes.
- Utilizing quantitative T1-mapping MRI to detect changes in longitudinal relaxation time (T1).
- Correlating T1 variations with H2O2 levels in the TME of NSCLC models.
Main Results:
- MIL-53(Fe)@MnO2 nanocomposites effectively shortened T1 relaxation time in the presence of H2O2.
- T1-mapping MRI detected significant T1 variations (approx. 2.6-fold increase vs. T1WI) differentiating H2O2 levels.
- Quantitative T1-mapping MRI provided reliable data for precise assessment of anti-cancer effects and NSCLC diagnosis.
Conclusions:
- The integrated approach of TME-adaptable nanoprobes and quantitative MRI offers a novel method for precise NSCLC diagnosis.
- This strategy enables accurate differentiation between drug-resistant and sensitive NSCLC based on TME H2O2 content.
- The findings pave the way for improved therapeutic strategies and outcomes in non-small cell lung cancer treatment.
More Related Videos
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
